The History
A drug before its receptor: how the Arizona team built Melanotan in the dark
Most drugs are built against a target the builder can see: a receptor somebody cloned, an enzyme somebody purified. Melanotan II runs the other way. The molecule was designed, tested, and pointed toward the clinic before its receptor existed as anything more than a suspicion — pharmacology done in the dark, on a target no one could yet name.
The hormone was never going to be a drug
α-MSH — alpha-melanocyte-stimulating hormone — is the body’s own tanning signal. It is a small linear peptide, thirteen amino acids long, and it is biologically brilliant and pharmaceutically useless. Serum proteases chew a linear peptide to fragments within minutes. Inject it and it would never survive long enough to do anything, let alone darken skin over days.
The team that set out to change that was at the University of Arizona — the chemist Victor Hruby, the biologist Mac Hadley, and their colleagues — working in a state whose sun made the problem feel urgent (where Melanotan came from). Their goal was photoprotection: a melanin layer built pharmacologically, before UV damage, instead of after it. Their obstacle was that the only molecule the body offered them for the job fell apart on arrival.
The instrument was a frog, not a receptor
They had to make the peptide stable and potent, and to know whether they had succeeded they needed a readout. Here is the part that defines the whole story: the melanocortin receptors did not exist yet. MC1R, the tanning receptor, would not be cloned until 1992 — twelve years after the chemistry that made this project famous. In the 1970s and 1980s the target was a black box.
So they measured the effect the old-fashioned way, with a bioassay. α-MSH makes pigment granules inside melanophores disperse, darkening the skin of a frog or lizard kept on the bench. Drop an analog on the skin, watch the color, and you have a potency readout. It was crude by modern standards and exactly right for the job: it measured the one thing the team actually cared about — does the skin darken?
Two swaps turned a transient signal into a drug
The chemistry is the elegant part. The team’s work converged on the active core of the hormone — a four-residue message sequence, His-Phe-Arg-Trp, that carries the signal — and around that core they built a drug by making exactly two edits.
At position four they swapped methionine for norleucine: the same side-chain shape, minus the sulfur atom that oxidizes and destabilizes the peptide. At position seven they swapped the natural L-phenylalanine for its mirror-image D-form, a change proteases cannot recognize and therefore cannot cut. The result was [Nle⁴, D-Phe⁷]α-MSH, published in 1980 by Sawyer, Hadley, Hruby and colleagues — better known as NDP-MSH. In the adenylate-cyclase assay it ran 26 times as potent as natural α-MSH, and it was “ultralong”: resistant to the enzymes that had made the natural hormone a non-starter.
From the linear analog to the cyclic one
NDP-MSH is the linear molecule that, developed further, became Melanotan I and eventually the approved drug afamelanotide (the two fates). But the same program also produced a second, tighter design: cyclic analogs, in which the pharmacophore is locked into its active shape by bridging the peptide into a ring. Cyclization made the molecule smaller, more resistant, and — critically — more potent at more places. That cyclic variant became Melanotan II.
Read that last clause with the hindsight the lab did not have. “More potent at more places” is a sentence you can only write after 1992. At the bench in the 1980s there was no list of places. The team optimized for the one output the frog skin could report — pigment — and could not have known they were also tuning the molecule toward the brain receptors that would later give it the appetite and arousal effects. Non-selectivity, in other words, was not a choice. It was the unavoidable shadow of designing a drug before the receptor map existed (why it did everything).
The dark has a cost
The receptor family was finally cloned in 1992 by Mountjoy, Cone, and colleagues — MC1R and MC2R first, the others shortly after. It landed like a late answer key. The frog skin, it turned out, had been reading MC1R all along; the bioassay had been faithfully reporting a single, real target that nobody could yet name.
The discipline of the dark is worth respecting. You do not need to see a receptor to build a drug for it; you need a faithful readout and good chemistry, and the Arizona team had both. But the dark also charges a price. A molecule optimized for “darkens skin” was never optimized for “touches one receptor and nothing else” — and that distinction is the difference between a medicine and everything that happened next. The compound got ahead of its own biology. Most of this site is about what followed (the PK story).
Common questions
Who invented Melanotan II?
Melanotan II was designed in the 1980s at the University of Arizona by the chemist Victor Hruby and the biologist Mac Hadley, with colleague Fahad Al-Obeidi among the named inventors. They were building stable, long-acting analogs of α-MSH, the body's own pigment signal.
How was Melanotan II designed before its receptors were known?
The melanocortin receptors were not cloned until 1992, so the Arizona team measured potency with a frog- and lizard-skin bioassay — α-MSH disperses pigment granules and darkens the skin. Around the hormone's active core they made two edits, replacing methionine with norleucine at position 4 and L-phenylalanine with D-phenylalanine at position 7. The result, NDP-MSH, became the basis of the Melanotan family.
What is NDP-MSH?
NDP-MSH, or [Nle⁴, D-Phe⁷]α-MSH, is the modified α-MSH analog published by Sawyer, Hadley, Hruby and colleagues in 1980. The two substitutions made it 26 times as potent as natural α-MSH in the adenylate-cyclase assay and resistant to the enzymes that rapidly degrade the hormone. It developed into Melanotan I, later approved as afamelanotide.